The Searle Company Limited is a Pakistan-based company, which is principally engaged in the manufacture of pharmaceutical and other consumer products. The Company's product portfolio in the pharmaceutical range includes therapeutic areas, such as cardiovascular, respiratory care, gastroenterology, pain management, central nervous system (CNS), orthocare, neuropsychiatry, probiotics, antibiotics, and nutritional care. Its pharmaceutical products Neubrol, Neubrol Forte, Hydryllin, Extor, Tramal, Peditral, Metrozine, Sustac, Ezium, Gravinate, Spiromide, Dextop, Metodine, Rotec, Metodine DF, Selanz, Relispa, Lumark, Decadron, Venofer, Aldomet, Sinemet, Noroxin, Ferinject, Janumet, and Maltofer, among others. Its consumer products include Enfagrow A+, Canderel, and Vitamin Water, among others. It also focuses on specialty generic branded portfolios and targeting differentiated products. Its subsidiaries include IBL HealthCare Limited, Searle Pharmaceuticals (Private) Limited, and others.
Metrics to compare | SEAR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSEARPeersSector | |
---|---|---|---|---|
P/E Ratio | −27.2x | 18.7x | −0.6x | |
PEG Ratio | 0.15 | 0.25 | 0.00 | |
Price/Book | 0.9x | 3.0x | 2.6x | |
Price / LTM Sales | 0.8x | 2.0x | 3.1x | |
Upside (Analyst Target) | 12.5% | 7.4% | 55.7% | |
Fair Value Upside | Unlock | −12.6% | 6.8% | Unlock |